Alkermes (Nasdaq: ALKS) reported positive results from a Phase 3 trial of its major depressive disorder treatment ALKS 5461. Shares of the biopharmaceutical leaped $12.11 to close at $55.62.
Alkermes reports positive trial data
October 21, 2016 at 20:04 PM EDT
